loader2
Login Open ICICI 3-in-1 Account

Divis Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Divi's Laboratories Ltd. 03 Feb 2025 13:37 PM

Q3FY25 Quarterly Result Announced for Divi's Laboratories Ltd.

Pharmaceuticals company Divi's Laboratories announced Q3FY25 results

  • Consolidated total income Rs 2,401 crore for Q3FY25 as against a consolidated total income of Rs 1,950 crore for Q3FY24.
  • Profit before tax (PBT) for Q3FY25 amounted to Rs 726 crore as against a PBT of Rs 489 crore for Q3FY24.
  • Profit after tax (PAT) for Q3FY25 amounted to Rs 589 crore as against a PAT of Rs 358 crore for Q3FY24.
  • For the Q3FY25, we have forex gain of Rs 10 crore as against a gain of Rs 18 crore during Q3FY24.

Result PDF

Pharmaceuticals company Divi's Laboratories announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Consolidated total income Rs 2,444 crore for Q2FY25 as against a consolidated total income of Rs 1,995 crore for Q2FY24.
  • Profit before tax (PBT) for the Q2FY25 amounted to Rs 722 crore as against a PBT of Rs 469 crore for Q2FY24.
  • Profit after tax (PAT) for the Q2FY25 amounted to Rs 510 crore as against a PAT of Rs 348 crore for Q2FY24.
  • Forex gain of Rs 29 crore as against a gain of Rs 11 crore during Q2FY24.

H1FY25 Financial Highlights:

  • Consolidated total income of Rs 4,640 crore as against a consolidated total income of Rs 3,854 crore during H1FY24.
  • PBT for H1FY25 came to Rs 1,326 crore as against Rs 961 crore for H1FY24.
  • PAT for H1FY25 came to Rs 940 crore as against Rs 704 crore for H1FY24.
  • Forex gain of Rs 28 crore against a gain of Rs 14 crore for H1FY24.

Result PDF

Pharmaceuticals company Divi's Laboratories announced Q1FY25 results:

Financial Highlights: 

  • Divi's Laboratories has earned a total income Rs 2,197 crore for Q1FY25 on a consolidated basis as against an income of Rs 1,859 crore for the corresponding quarter of last year.
  • Profit before Tax (PBT) for the current quarter amounted to Rs 604 crore as against a PBT of Rs 492 crore for the corresponding quarter of the last year and a PBT of Rs 713 crore for the fourth quarter of last year.
  • The Company earned a Profit after Tax (PAT) of Rs 430 crore for the current quarter as against a PAT of Rs 356 crore for the corresponding quarter of the last year. PAT for the fourth quarter of last year was Rs 538 crore.
  • Forex loss for the current quarter amounted to Rs 1 crore as against a gain of Rs 3 crore during the corresponding quarter of the last year.

Result PDF

Pharmaceuticals company Divi's Laboratories announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

  • Total Income: Rs 1,950 crore, compared to Rs 1,821 crore in the corresponding quarter of the previous year.
  • Material Consumption: Approximately 39% of sales revenue.
  • Profit Before Tax (PBT): Rs 489 crore, compared to Rs 435 crore in the corresponding quarter of the previous year.
  • Profit After Tax (PAT): Rs 358 crore, compared to Rs 306 crore in the corresponding quarter of the previous year.

Standalone Q3FY24:

  • Total Income: Recorded at Rs 1,902 crore in Q3FY24 compared to Rs 1,807 crore in Q3FY23.
  • Profit Before Tax (PBT): Stood at Rs 490 crore in Q3FY24, up from Rs 439 crore in Q3FY23.
  • Profit After Tax (PAT): Amounted to Rs 358 crore in Q3FY24, higher than the Rs 310 crore in Q3FY23.
  • Forex Gain: Registered at Rs 17 crore in Q3FY24, decreased from Rs 49 crore in Q3FY23.

Consolidated 9MFY24:

  • Total Income: Rs 5,804 crore, compared to Rs 6,099 crore in the corresponding previous period.
  • Profit After Tax (PAT): Rs 1,062 crore, compared to Rs 1,502 crore in the corresponding previous period.
  • Forex Gain: Rs 32 crore, compared to Rs 134 crore in the previous 9-month period.

Standalone 9MFY24:

  • Total Income: For 9MFY24, it amounted to Rs 5,665 crore, down from Rs 6,003 crore in 9MFY23.
  • Profit Before Tax (PBT): For 9MFY24, it was Rs 1,432 crore, a decrease from Rs 1,886 crore in 9MFY23.
  • Profit After Tax (PAT): For 9MFY24, it reached Rs 1,045 crore, down from Rs 1,489 crore in 9MFY23.
  • Forex Gain: For 9MFY24, it stood at Rs 29 crore, a decline from Rs 137 crore in 9MFY23.

Result PDF

Pharmaceuticals company Divi's Laboratories announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Total income for Q2FY24 increased from Rs 1,935 crore to Rs 1,995 crore in Q2FY23.
    • PBT for Q2FY24 decreased from Rs 615 crore to Rs 469 crore in Q2FY23.
    • PAT for Q2FY24 decreased from Rs 493 crore to Rs 348 crore in Q2FY23.
    • Forex Gain of Rs 11 crore compared to Rs 31 crore in Q2FY23
  • H1FY24:
    • Total income for H1FY24 decreased from Rs 4,278 crore to Rs 3,854 crore in H1FY23.
    • PAT for H1FY24 decreased from Rs 1,196 crore to Rs 704 crore in H1FY23.
    • Forex Gain of Rs 14 crore compared to Rs 87 crore in H1FY23.

 

 

Result PDF

Pharmaceuticals company Divi's Laboratories announced Q1FY24 results:

  • Total income of Rs 1,859 crore for Q1FY24 on a consolidated basis as against an income of Rs 2,343 crore for Q1FY23.
  • Profit before Tax (PBT) for Q1FY24 amounted to Rs 492 crore as against a PBT of Rs 852 crore for Q1FY23 and a PBT of Rs 466 crore for Q4FY23.
  • The Company earned a Profit after Tax (PAT) of Rs 356 crore for Q1FY24 as against a PAT of Rs 702 crore for Q1FY23. PAT for Q4FY23 was Rs 321 crore.
  • Forex gain for Q1FY24 amounted to Rs 3 crore as against a gain of Rs 56 crore during Q1FY23.

 

 

Result PDF

Pharmaceuticals company Divi's Laboratories announced consolidated FY23 results:

  • Total income of Rs 8,112 crore for FY23 as against Rs 9,074 crore during FY22
  • Total income is about 11 % lower than FY22 because of a significantly lower volume of covid situational opportunity
  • PBT for FY23 came to Rs 2,369 crore as against Rs 3,684 crore for FY22
  • PAT for FY23 amounted to Rs 1,823 crore as against a PAT of Rs 2,960 crore
  • The board of directors of the company has proposed a dividend of Rs 30 per share of face value Rs 2 each i.e., 1500% for FY23, subject to approval of members.

 

 

 

Result PDF

Pharmaceuticals firm Divi's Laboratories announced Q3FY23 results:

Consolidated Q3FY23 & 9MFY23:

  • Divi’s Laboratories has earned a consolidated total income of Rs 1,822 crores for Q3FY23 as against a total income of Rs 2,510 crores during the corresponding quarter of last year.
  • Profit before Tax (PBT) for Q3FY23 accounted to Rs 436 crores, as against a PBT of Rs 1,034 crores during the corresponding quarter of last year.
  • Profit after Tax (PAT) for the current is Rs 307 crores as against a PAT of Rs 902 crores for the corresponding quarter of last year.
  • For the 9MFY23, the company earned a PAT of Rs 1,502 crores on a total income of Rs 6,099 crores, as against a PAT of Rs 2,066 crores on a total income of Rs 6,503 crores during the corresponding previous period.

 

 

Result PDF

Divi's Laboratories announced Q2FY23 results:

  • Divi's Laboratories Limited (Divi's/the Company) has earned a consolidated total income of Rs 1,935 crore for Q2FY23 as against a consolidated total income of Rs 2,007 crore in the corresponding Q2FY22
  • Profit before tax (PBT) for Q2FY23 amounted to Rs 615 crore as against a PBT of Rs 760 crore for the corresponding Q2FY22
  • Profit after tax (PAT) for Q2FY23 amounted to Rs 494 crore as against a PAT of Rs 606 crore for Q2FY22
  • For Q2FY23, we have a forex gain of Rs 31 crore as against a loss of  Rs 7 crore during Q2FY22.
  • For H1FY23, the company earned a consolidated total income of Rs 4,278 crore as against a consolidated total income of Rs 3,996 crore during H1FY22
  • PAT for H1FY23 to Rs 1,196 crore as against Rs 1,164 crore for the previous H1FY22. For H1FY23, we had a forex gain of Rs 87 crore as against a gain of Rs 13 crore during the corresponding H1FY22.

 

Result PDF

Pharmaceuticals firm Divi's Laboratories announced Q1FY23 Result :

  • Divi's Laboratories has earned a total income of Rs  2343 crores for the 1st quarter of the year 2022-23 on a consolidated basis as against an income of Rs 1997 crores for the corresponding quarter of last year.
  • Profit before Tax (PBT) for the quarter amounted to Rs 851 crores as against a PBT of Rs 814 crores for the corresponding quarter of the last year. The Company earned a Profit after Tax (PAT) of Rs 702 crores for the current quarter as against a PAT of Rs 557 crores for the corresponding quarter of the last year.
  • Forex gain for the current quarter amounted to Rs 56 crores as against a gain of Rs  20 crores during the corresponding quarter of the last year.

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app